These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 11396233)

  • 1. Clinical utility of serum HER-2/neu testing on the Bayer Immuno 1 automated system in breast cancer.
    Cook GB; Neaman IE; Goldblatt JL; Cambetas DR; Hussain M; Lüftner D; Yeung KK; Chan DW; Schwartz MK; Allard WJ
    Anticancer Res; 2001; 21(2B):1465-70. PubMed ID: 11396233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The course of serum HER-2/neu levels as an independent prognostic factor for survival in metastatic breast cancer.
    Schippinger W; Regitnig P; Bauernhofer T; Ploner F; Hofmann G; Krippl P; Wehrschütz M; Lax S; Carney W; Neumann R; Wernecke KD; Samonigg H
    Oncol Rep; 2004 Jun; 11(6):1331-6. PubMed ID: 15138574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER-2/neu determination in blood plasma of patients with HER-2/neu overexpressing metastasized breast cancer: a longitudinal study.
    Hoopmann M; Neumann R; Tanasale T; Schöndorf T
    Anticancer Res; 2003; 23(2A):1031-4. PubMed ID: 12820343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical utility of serum human epidermal receptor-2/neu detection in breast cancer patients.
    Thriveni K; Deshmane V; Bapsy PP; Krishnamoorthy L; Ramaswamy G
    Indian J Med Res; 2007 Feb; 125(2):137-42. PubMed ID: 17431282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Serum her-2/neu level and related factors in patients with breast cancer].
    Yuan P; Xu BH; Zhang C; Qi J
    Zhonghua Zhong Liu Za Zhi; 2003 Nov; 25(6):573-4. PubMed ID: 14690565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High and differential expression of HER-2/neu extracellular domain in bilateral ductal fluids from women with unilateral invasive breast cancer.
    Kuerer HM; Thompson PA; Krishnamurthy S; Fritsche HA; Marcy SM; Babiera GV; Singletary SE; Cristofanilli M; Sneige N; Hunt KK
    Clin Cancer Res; 2003 Feb; 9(2):601-5. PubMed ID: 12576424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy.
    Pectasides D; Gaglia A; Arapantoni-Dadioti P; Bobota A; Valavanis C; Kostopoulou V; Mylonakis N; Karabelis A; Pectasides M; Economopoulos T
    Anticancer Res; 2006; 26(1B):647-53. PubMed ID: 16739334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy.
    Sandri MT; Johansson HA; Zorzino L; Salvatici M; Passerini R; Maisonneuve P; Rocca A; Peruzzotti G; Colleoni M
    Cancer; 2007 Aug; 110(3):509-17. PubMed ID: 17559147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.
    Esteva FJ; Cheli CD; Fritsche H; Fornier M; Slamon D; Thiel RP; Luftner D; Ghani F
    Breast Cancer Res; 2005; 7(4):R436-43. PubMed ID: 15987448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring therapy by serum HER-2/neu.
    Schwartz MK; Smith C; Schwartz DC; Dnistrian A; Neiman I
    Int J Biol Markers; 2000; 15(4):324-9. PubMed ID: 11192828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ADVIA Centaur HER-2/neu shows value in monitoring patients with metastatic breast cancer.
    Lüftner D; Cheli C; Mickelson K; Sampson E; Possinger K
    Int J Biol Markers; 2004; 19(3):175-82. PubMed ID: 15503818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Change of HER-2/neu status in a subset of distant metastases from breast carcinomas.
    Regitnig P; Schippinger W; Lindbauer M; Samonigg H; Lax SF
    J Pathol; 2004 Aug; 203(4):918-26. PubMed ID: 15258994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy.
    Mazouni C; Hall A; Broglio K; Fritsche H; Andre F; Esteva FJ; Hortobagyi GN; Buzdar AU; Pusztai L; Cristofanilli M
    Cancer; 2007 Feb; 109(3):496-501. PubMed ID: 17149760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Serum HER-2 determination using a centauer HER-2/neu kit (CLIA method) in metastatic breast cancer].
    Kan N; Yoshikawa S
    Gan To Kagaku Ryoho; 2009 May; 36(5):779-83. PubMed ID: 19461177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum levels of shed Her2/neu protein in men with prostate cancer correlate with disease progression.
    Osman I; Mikhail M; Shuch B; Clute M; Cheli CD; Ghani F; Thiel RP; Taneja SS
    J Urol; 2005 Dec; 174(6):2174-7. PubMed ID: 16280758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serological and immunohistochemical HER-2/neu statuses do not correlate and lack prognostic value for ovarian cancer patients.
    Hoopmann M; Sachse K; Valter MM; Becker M; Neumann R; Ortmann M; Göhring UJ; Thomas A; Mallmann P; Schöndorf T
    Eur J Cancer Care (Engl); 2010 Nov; 19(6):809-15. PubMed ID: 20105224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma levels of HER-2/neu, tumor type M2 pyruvate kinase and its tyrosine-phosphorylated metabolite in advanced breast cancer.
    Lüftner D; Mazurek S; Henschke P; Mesterharm J; Schildhauer S; Geppert R; Wernecke KD; Possinger K
    Anticancer Res; 2003; 23(2A):991-7. PubMed ID: 12820337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of the measurement of serum extracellular domain of HER-2/neu protein with CLIA method.
    Kuroda N; Kontani K; Kajikawa T; Taminato T
    Rinsho Byori; 2010 Jun; 58(6):541-52. PubMed ID: 20662264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER-2/neu gene product in serum--an oncoprotein in the diagnosis and therapy of breast carcinoma.
    Schulze G
    Anticancer Res; 2003; 23(2A):1007-10. PubMed ID: 12820339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy.
    Lipton A; Leitzel K; Ali SM; Demers L; Harvey HA; Chaudri-Ross HA; Evans D; Lang R; Hackl W; Hamer P; Carney W
    Cancer; 2005 Jul; 104(2):257-63. PubMed ID: 15952182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.